CYR61 human
SIGMA/SRP3024 - recombinant, expressed in E. coli, ≥95% (SDS-PAGE), ≥95% (HPLC), suitable for cell culture
Synonym: CCN1; GIGI protein
Product Type: Chemical
This image is provided for informative purposes only and does not represent an actual product label. It should not be used as a substitute for official product labeling.
| assay | ≥95% (HPLC) |
| ≥95% (SDS-PAGE) | |
| biological source | human |
| color | white to off-white |
| form | lyophilized |
| impurities | <0.1 EU/μg endotoxin, tested |
| mol wt | 39.5 kDa |
| packaging | pkg of 20 μg |
| potency | ≤0.1 ng/mL |
| recombinant | expressed in E. coli |
| shipped in | wet ice |
| storage temp. | −20°C |
| technique(s) | cell culture | mammalian: suitable |
| UniProt accession no. | O00622   |
| Biochem/physiol Actions: | CYR61 is a member of the CCN family of secreted cysteine rich regulatory proteins. Recombinant human CYR61 is a 39.5 kDa protein containing 357 amino acid residues. It is composed of four distinct structural domains (modules); the IGF binding protein (IGFBP) domain, the von Willebrand Factor C (VWFC) domain, the Thrombospondin type-I (TSP type-1) domain, and a C-terminal cysteine knot-like domain (CTCK). |
| General description: | CYR61 is a member of the CCN family of secreted cysteine rich regulatory proteins. CYR61 induces angiogenesis by stimulating the proliferation, migration, and adhesion of endothelial cells. Cell migration and adhesion are mediated through binding to specific cell surface integrins and to heparin sulfate proteoglycans. Increased expression of CYR61 is associated with several types of cancer, and correlates with the progression and estrogen independence of human breast cancers. Recombinant human CYR61 is a 39.5 kDa protein containing 357 amino acid residues. It is composed of four distinct structural domains (modules); the IGF binding protein (IGFBP) domain, the von Willebrand Factor C (VWFC) domain, the Thrombospondin type-I (TSP type-1) domain, and a C-terminal cysteine knot-like domain (CTCK). |
| Other Notes: | MTCPAACHCP LEAPKCAPGV GLVRDGCGCC KVCAKQLNED CSKTQPCDHT KGLECNFGAS STALKGICRA QSEGRPCEYN SRIYQNGESF QPNCKHQCTC IDGAVGCIPL CPQELSLPNL GCPNPRLVKV TGQCCEEWVC DEDSIKDPME DQDGLLGKEL GFDASEVELT RNNELIAVGK GSSLKRLPVF GMEPRILYNP LQGQKCIVQT TSWSQCSKTC GTGISTRVTN DNPECRLVKE TRICEVRPCG QPVYSSLKKG KKCSKTKKSP EPVRFTYAGC LSVKKYRPKY CGSCVDGRCC TPQLTRTVKM RFRCEDGETF SKNVMMIQSC KCNYNCPHAN EAAFPFYRLF NDIHKFRD |
| Physical form: | Lyophilized from 10 mM Sodium Citrate, pH 3.0 + 50 mM NaCl. |
| Preparation Note: | Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥95% (HPLC); ≥95% (SDS-PAGE) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |